<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04943276</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-59863</org_study_id>
    <nct_id>NCT04943276</nct_id>
  </id_info>
  <brief_title>A Novel Noninvasive Thermoregulatory Device for Postural Tachycardia Syndrome</brief_title>
  <official_title>A Novel Noninvasive Thermoregulatory Device for Postural Tachycardia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Embr Labs, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hope to learn the feasibility and preliminary efficacy of the Embr device&#xD;
      for improving thermal comfort in individuals with POTS and impaired thermoregulation.&#xD;
      Feasibility will be assessed via usage of the Embr device and participant feedback.&#xD;
      Preliminary efficacy measures will include temperature-related symptoms and temperature-&#xD;
      related quality of life in individuals with POTS and impaired thermoregulation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Compass-31 survey at study endpoint</measure>
    <time_frame>Baseline and end of study ( 4 weeks)</time_frame>
    <description>Compass 31 score ranges in value from 0 to 100. A score of 0 indicates no autonomic symptoms, while more-severe autonomic symptoms correspond to higher values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in Pittsburg Sleep Quality Index (PSQI) at study endpoint</measure>
    <time_frame>Baseline and end of study ( 4 weeks)</time_frame>
    <description>PSQI score ranges in value from 0 to 21. A score of 0 indicates no sleep difficulties, while more-severe sleep difficulties correspond to higher values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in Insomnia Severity Scale Index (ISI) at study endpoint</measure>
    <time_frame>Baseline and end of study ( 4 weeks)</time_frame>
    <description>Scale range is 0-28, with 0 indicating absence of insomnia and 28 indicating severe insomnia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Temperature Quality of life Questionnaire</measure>
    <time_frame>Week 1,2,3,4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Temperature related daily interference scale</measure>
    <time_frame>Week 1,2,3,4</time_frame>
    <description>Scale range is 0-100, with a higher score indicating more problems with thermoregulation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OCEAN Temperature Related Psychogenic Questionnaire</measure>
    <time_frame>Week 1,2,3,4</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Postural Tachycardia Syndrome</condition>
  <arm_group>
    <arm_group_label>Embr Watch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the device and a technical onboarding video 3 days prior to study start to allow time for familiarization with the device and troubleshooting any technical questions or problems prior to study start. The study will consist of baseline measurements prior to using the Embr device and weekly outcome assessments at Week 1, 2, 3, and 4</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Embr Device</intervention_name>
    <description>The Embr thermal device will be worn at all times from study start to the study endpoint.</description>
    <arm_group_label>Embr Watch</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of POTS&#xD;
&#xD;
          -  Participant self-report of heat or cold intolerance&#xD;
&#xD;
          -  Willingness to wear the Embr device for 3 weeks, charging the device daily, and&#xD;
&#xD;
          -  Have a working smartphone (iPhone 6 or greater; or Android 8.0 or greater&#xD;
&#xD;
          -  Comfortable downloading and using the companion app on their phone&#xD;
&#xD;
          -  Able to provide informed written consent&#xD;
&#xD;
          -  Able to complete written questionnaires&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior or current use of the study device&#xD;
&#xD;
          -  Hypohidrosis, hyperhidrosis, or anhidrosis, as determined by sudomotor testing;&#xD;
             peripheral neuropathy; perimenopausal, menopausal, postmenopausal state; temperature&#xD;
             intolerance due to other medical disorders (i.e. malignancy, systemic autoimmune&#xD;
             disease)&#xD;
&#xD;
          -  Medications known to affect sweat function&#xD;
&#xD;
          -  Non-English speaking&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchell Miglis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 23, 2021</study_first_submitted>
  <study_first_submitted_qc>June 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2021</study_first_posted>
  <last_update_submitted>July 11, 2021</last_update_submitted>
  <last_update_submitted_qc>July 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Mitchell Miglis</investigator_full_name>
    <investigator_title>Clinical Assistant Professor, Neurology and Neurological Sciences</investigator_title>
  </responsible_party>
  <keyword>Thermoregulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postural Orthostatic Tachycardia Syndrome</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All individual participant data collected during the trial, after de-identification. Only this de-identified data will be shared with the Embr team.&#xD;
PHI data will not be shared.</ipd_description>
    <ipd_time_frame>After study end. ( 1 Year after enrollment begins)</ipd_time_frame>
    <ipd_access_criteria>Only Embr labs research team will have access to the de-identified data</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

